Article Text

Download PDFPDF
Prioritising treatment among people who inject drugs in order to eliminate hepatitis C: addressing reluctance with sound economic analyses
  1. Yvan J-F Hutin,
  2. Stefan Z Wiktor
  1. Global Hepatitis Programme, World Health Organization, Geneva, Switzerland
  1. Correspondence to Dr Yvan J-F Hutin, Global Hepatitis Programme, World Health Organization, Avenue Appia, 20, Geneva 1211, Switzerland; hutiny{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

In May 2016, the World Health Assembly, the governing body of WHO, endorsed the first-ever global hepatitis strategy.1 This document, termed the Global Health Sector Strategy on Viral Hepatitis (GHSS-VH), proposes ambitious prevention and treatment targets with the ultimate goal of eliminating hepatitis as a public health threat by 2030. The GHSS-VH defines elimination as a 90% reduction in incidence of chronic HBV and HCV infections and a 65% reduction in hepatitis-related mortality. Achieving the goals of the global strategy will require scaling up prevention and treatment services, which in turn will require increases in financial resources and political commitment. In addition, national health planners will need to decide how best to allocate these resources so that they have maximal impact. A solid understanding of the epidemiology of hepatitis infection in the country, in particular identifying groups at highest risk of infection and those at highest risk of death should be the basis of a sound national treatment plan that can meet the incidence and mortality goals of GHSS-VH.

In this issue, Scott et al2 developed a mathematical model to study which treatment strategies would most effectively and efficiently eliminate hepatitis C in Australia, based on the WHO strategy's goals. As in most high-income countries, HCV infection …

View Full Text


  • Contributors YJ-FH and SZW drafted, edited and finalised the editorial together.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.